vs
Side-by-side financial comparison of EDGEWELL PERSONAL CARE Co (EPC) and MADRIGAL PHARMACEUTICALS, INC. (MDGL). Click either name above to swap in a different company.
EDGEWELL PERSONAL CARE Co is the larger business by last-quarter revenue ($422.8M vs $321.1M, roughly 1.3× MADRIGAL PHARMACEUTICALS, INC.). EDGEWELL PERSONAL CARE Co runs the higher net margin — -15.5% vs -18.2%, a 2.7% gap on every dollar of revenue. On growth, MADRIGAL PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (210.8% vs -11.6%). MADRIGAL PHARMACEUTICALS, INC. produced more free cash flow last quarter ($-133.8M vs $-137.5M).
The Edgewell Personal Care Company is an American multinational consumer products company headquartered in Shelton, Connecticut. It was formed in 2015 following the corporate spin-off from Energizer Holdings, Inc..
Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.
EPC vs MDGL — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $422.8M | $321.1M |
| Net Profit | $-65.7M | $-58.6M |
| Gross Margin | 38.1% | — |
| Operating Margin | -4.5% | -18.6% |
| Net Margin | -15.5% | -18.2% |
| Revenue YoY | -11.6% | 210.8% |
| Net Profit YoY | -3028.6% | 1.4% |
| EPS (diluted) | $-1.41 | $-2.55 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $422.8M | $321.1M | ||
| Q3 25 | $600.5M | $287.3M | ||
| Q2 25 | $627.2M | $212.8M | ||
| Q1 25 | $580.7M | $137.3M | ||
| Q4 24 | $415.1M | $103.3M | ||
| Q3 24 | $517.6M | $62.2M | ||
| Q2 24 | $647.8M | — | ||
| Q1 24 | $599.4M | $0 |
| Q4 25 | $-65.7M | $-58.6M | ||
| Q3 25 | $-30.6M | $-114.2M | ||
| Q2 25 | $29.1M | $-42.3M | ||
| Q1 25 | $29.0M | $-73.2M | ||
| Q4 24 | $-2.1M | $-59.4M | ||
| Q3 24 | $8.8M | $-107.0M | ||
| Q2 24 | $49.0M | — | ||
| Q1 24 | $36.0M | $-147.5M |
| Q4 25 | 38.1% | — | ||
| Q3 25 | 37.9% | — | ||
| Q2 25 | 42.8% | — | ||
| Q1 25 | 44.1% | 96.7% | ||
| Q4 24 | 41.6% | — | ||
| Q3 24 | 41.1% | — | ||
| Q2 24 | 44.3% | — | ||
| Q1 24 | 43.1% | — |
| Q4 25 | -4.5% | -18.6% | ||
| Q3 25 | -4.2% | -39.7% | ||
| Q2 25 | 8.6% | -22.2% | ||
| Q1 25 | 10.1% | -57.8% | ||
| Q4 24 | 2.2% | -64.8% | ||
| Q3 24 | 3.9% | -187.1% | ||
| Q2 24 | 12.8% | — | ||
| Q1 24 | 11.7% | — |
| Q4 25 | -15.5% | -18.2% | ||
| Q3 25 | -5.1% | -39.8% | ||
| Q2 25 | 4.6% | -19.9% | ||
| Q1 25 | 5.0% | -53.4% | ||
| Q4 24 | -0.5% | -57.5% | ||
| Q3 24 | 1.7% | -172.0% | ||
| Q2 24 | 7.6% | — | ||
| Q1 24 | 6.0% | — |
| Q4 25 | $-1.41 | $-2.55 | ||
| Q3 25 | $-0.65 | $-5.08 | ||
| Q2 25 | $0.62 | $-1.90 | ||
| Q1 25 | $0.60 | $-3.32 | ||
| Q4 24 | $-0.04 | $-2.50 | ||
| Q3 24 | $0.18 | $-4.92 | ||
| Q2 24 | $0.98 | — | ||
| Q1 24 | $0.72 | $-7.38 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $198.7M |
| Total DebtLower is stronger | $1.5B | $339.9M |
| Stockholders' EquityBook value | $1.5B | $602.7M |
| Total Assets | $3.8B | $1.3B |
| Debt / EquityLower = less leverage | 1.03× | 0.56× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $198.7M | ||
| Q3 25 | — | $295.7M | ||
| Q2 25 | — | $186.2M | ||
| Q1 25 | — | $183.6M | ||
| Q4 24 | — | $100.0M | ||
| Q3 24 | $209.1M | $232.7M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $622.5M |
| Q4 25 | $1.5B | $339.9M | ||
| Q3 25 | $1.4B | $339.8M | ||
| Q2 25 | $1.4B | $118.4M | ||
| Q1 25 | $1.4B | $118.0M | ||
| Q4 24 | $1.4B | $117.6M | ||
| Q3 24 | $1.3B | $117.1M | ||
| Q2 24 | $1.3B | — | ||
| Q1 24 | $1.4B | $116.1M |
| Q4 25 | $1.5B | $602.7M | ||
| Q3 25 | $1.6B | $625.7M | ||
| Q2 25 | $1.6B | $696.0M | ||
| Q1 25 | $1.5B | $710.6M | ||
| Q4 24 | $1.5B | $754.4M | ||
| Q3 24 | $1.6B | $777.2M | ||
| Q2 24 | $1.6B | — | ||
| Q1 24 | $1.6B | $850.8M |
| Q4 25 | $3.8B | $1.3B | ||
| Q3 25 | $3.8B | $1.4B | ||
| Q2 25 | $3.8B | $1.0B | ||
| Q1 25 | $3.8B | $996.6M | ||
| Q4 24 | $3.7B | $1.0B | ||
| Q3 24 | $3.7B | $1.1B | ||
| Q2 24 | $3.7B | — | ||
| Q1 24 | $3.8B | $1.1B |
| Q4 25 | 1.03× | 0.56× | ||
| Q3 25 | 0.89× | 0.54× | ||
| Q2 25 | 0.88× | 0.17× | ||
| Q1 25 | 0.95× | 0.17× | ||
| Q4 24 | 0.97× | 0.16× | ||
| Q3 24 | 0.81× | 0.15× | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | 0.14× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-125.9M | $-133.5M |
| Free Cash FlowOCF − Capex | $-137.5M | $-133.8M |
| FCF MarginFCF / Revenue | -32.5% | -41.7% |
| Capex IntensityCapex / Revenue | 2.7% | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $36.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-125.9M | $-133.5M | ||
| Q3 25 | $74.1M | $79.8M | ||
| Q2 25 | $114.8M | $-47.1M | ||
| Q1 25 | $45.1M | $-88.9M | ||
| Q4 24 | $-115.6M | $-104.5M | ||
| Q3 24 | $-388.3M | $-67.0M | ||
| Q2 24 | $101.2M | — | ||
| Q1 24 | $129.0M | $-149.2M |
| Q4 25 | $-137.5M | $-133.8M | ||
| Q3 25 | $46.5M | $79.0M | ||
| Q2 25 | $99.3M | — | ||
| Q1 25 | $28.0M | — | ||
| Q4 24 | $-132.4M | $-104.7M | ||
| Q3 24 | $-414.2M | $-67.8M | ||
| Q2 24 | $88.6M | — | ||
| Q1 24 | $117.5M | $-149.5M |
| Q4 25 | -32.5% | -41.7% | ||
| Q3 25 | 7.7% | 27.5% | ||
| Q2 25 | 15.8% | — | ||
| Q1 25 | 4.8% | — | ||
| Q4 24 | -31.9% | -101.3% | ||
| Q3 24 | -80.0% | -109.0% | ||
| Q2 24 | 13.7% | — | ||
| Q1 24 | 19.6% | — |
| Q4 25 | 2.7% | 0.1% | ||
| Q3 25 | 4.6% | 0.3% | ||
| Q2 25 | 2.5% | 0.0% | ||
| Q1 25 | 2.9% | 0.0% | ||
| Q4 24 | 4.0% | 0.2% | ||
| Q3 24 | 5.0% | 1.3% | ||
| Q2 24 | 1.9% | — | ||
| Q1 24 | 1.9% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 3.95× | — | ||
| Q1 25 | 1.56× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -44.13× | — | ||
| Q2 24 | 2.07× | — | ||
| Q1 24 | 3.58× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EPC
| Other | $242.0M | 57% |
| Sunand Skin Care Segment | $131.5M | 31% |
| Shavinggelsandcreams | $32.3M | 8% |
| Wipes And Other Skin Care Products | $17.0M | 4% |
MDGL
| Rebates Customer Fees Credits Co Pay Assistance And Other | $208.5M | 65% |
| Other | $76.0M | 24% |
| Chargebacks Discounts For Prompt Pay And Other Allowances | $36.6M | 11% |
